SK Capital Partners in discussions to create an integrated global API CDMO leader
The private investment firm plans to acquire SEQENS and merge it with Wavelength Pharmaceuticals
SK Capital Partners has entered into exclusive discussions to acquire a majority stake in SEQENS — an integrated developer and manufacturer of active pharmaceutical ingredients (APIs), advanced drug intermediates and specialty ingredients.
The company also plans to merge one of its portfolio companies, Wavelength Pharmaceuticals, to create a global leader in the API & CDMO sectors.
Both elements of the deal are expected to complete by the end of 2021.
SEQENS is headquartered in France, and through its 3000 employees in 19 production sites and seven R&D centers around the world, generates an annual turnover of over €1 billion.
The company focuses on critical consumer care analgesic APIs, offering a broad portfolio of generic APIs and intermediates, as well as custom development and manufacturing services across a wide range of pharmaceutical technologies.
Wavelength Pharmaceuticals, a developer and manufacturer of APIs, produces more than 630 metric tons of commercial products every year and offers a full range of API CDMO services from preclinical grams to multi-ton commercial scale.
The proposed merger will create a scaled leader of global industrial footprint and further extend both companies’ broad portfolio of products, services and advanced pharmaceutical technologies; it could also increase the group’s industrial footprint, its product and technology portfolio.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.